What is the recommended course of action for patients with increased ASCVD risk with severe statin-associated side effects or recurrent SAMS?
In patients at increased ASCVD risk with severe statin-associated side effects or recurrent SAMS, nonstatin therapy should be considered when there is net benefit and risk.